|March 20, 2014|
|07:35 EDT||BONE||Bacterin announces publication of OsteoSponge clinical results|
Bacterin announced that results utilizing OsteoSponge bone graft for foot and ankle arthrodeses procedures has been published in the peer-reviewed journal Orthopedics. The article reports a prospective analysis of 25 patients who underwent foot and ankle arthrodesis involving 45 total joints. Results indicated that 96% of patients showed radiographic fusion at 6 and 12 months postoperative assessment, with a 97.4% overall fusion rate. Pain was assessed pre and postoperatively via visual analog scale, with statistically significant improvements at 6 and 12 months relative to preoperative pain scores. Functional outcomes were significantly improved at 6 and 12 months compared with preoperative assessment according to American Orthopaedic Foot and Ankle Society scores.
News For BONE From The Last 14 Days
Check below for free stories on BONE the last two weeks.
|August 1, 2014|
|08:38 EDT||BONE||Bacterin 1.1M share Spot Secondary priced at $5.70|
Subscribe for More Information
|July 31, 2014|
|16:07 EDT||BONE||Bacterin files to sell common stock and warrants, no amount given|
Net proceeds from the offering are expected to be used for working capital and general corporate purposes including the continued expansion of the company's sales force and increasing inventory levels to support anticipated future growth. Northland Securities, Inc. is acting as the sole book-running manager for the offering.
|July 23, 2014|
|07:31 EDT||BONE||Bacterin announces 1 for 10 reverse split of common stock|
Bacterin announced that a 1:10 reverse split of its common stock will be effective at the close of business on Friday, July 25 and in effect for trading purposes on Monday, July 28. The reverse stock split was approved by the company's shareholders at the 2014 Annual Shareholder's Meeting held June 11.
|July 21, 2014|
|18:00 EDT||BONE||Bacterin reports preliminary Q2 revenue $8.75M-$8.85M, consensus $8.93M|
The company sees preliminary Q2 operating loss ($1.5M)-($1.4M). The company sees preliminary Q2 EBITDA of ($800K)-($900K). Gross margin for Q2 is expected to be 61%-63%.